Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors
Keywords
-
Journal
LANCET
Volume 401, Issue 10388, Pages 1571-1583
Publisher
Elsevier BV
Online
2023-04-26
DOI
10.1016/s0140-6736(23)00464-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prediction of survival with intensive chemotherapy in acute myeloid leukemia
- (2022) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy
- (2022) Eunice S. Wang et al. BLOOD
- Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel
- (2022) Hartmut Döhner et al. BLOOD
- Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
- (2021) Dongwoo Kang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
- (2020) Tomoya Aikawa et al. Oncotarget
- Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Heuser et al. ANNALS OF ONCOLOGY
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
- (2020) Li Xuan et al. LANCET ONCOLOGY
- FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
- (2020) Vanessa E. Kennedy et al. Frontiers in Oncology
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
- (2019) Jorge E Cortes et al. LANCET ONCOLOGY
- Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia
- (2019) Masahiro Sakaguchi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
- (2019) Hitoshi Kiyoi et al. CANCER SCIENCE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
- (2016) Steven Knapper et al. BLOOD
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
- (2016) I De Kouchkovsky et al. Blood Cancer Journal
- A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activatingFLT3mutations
- (2015) Walter Fiedler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis
- (2015) Mary-Elizabeth M. Percival et al. CANCER
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
- (2015) Julie A. Zorn et al. PLoS One
- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
- (2014) R. F. Schlenk et al. BLOOD
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
- (2013) M. Levis Hematology-American Society of Hematology Education Program
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
- (2009) K. W. Pratz et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started